Peter Donato Joins Diality as Chief Financial Officer

Diality Inc. has named financial and life sciences veteran Peter Donato as its chief financial officer (CFO).

Donato joins the company as it continues to enroll patients in the PRESCRIBE Diality Home Hemodialysis Clinical Trial, which is evaluating the Moda-flx Hemodialysis System before a planned limited market release next year.

“Peter joins Diality at a pivotal time, as we prepare for the commercialization of Moda-flx to help more nephrologists and care teams improve the daily living of dialysis patients,” Diality CEO Osman Khawar, M.D., said. “With his leadership, I am confident we will build and sustain profitable business models that enable us to make a long and meaningful impact in kidney care.”

Donato has nearly 35 years of financial leadership experience, including more than 23 years of both public and private company roles primarily in the life science industry. Before joining Diality, he was CFO of heart failure device company Impulse Dynamics, and before that, chief financial and administrative officer of companion pet health company Zomedica. Donato also served as executive vice president and CFO of Standard Bariatrics, sold to Teleflex in a $300 million deal in 2022. Additionally, he led Neuronetics’ IPO in 2018. Donato’s prior executive experience includes Assurex Health, which successfully exited in a $410 million sale to Myriad in 2016, Bovie Medical (now Apyx Medical), Cyberonics (now LivaNova), and Iris International (formerly IRIS).

The Moda-flx Hemodialysis System is designed to empower kidney care professionals with a wide range of variable flow rates, integrated RO water filtration, and an intuitive, easy-to-use graphical user interface. The system provides clinicians the flexibility to easily customize each hemodialysis experience according to patient needs in one integrated interface. The platform’s compact footprint and mobility enable seamless integration and transportation between dialysis care settings. The Moda-flx Hemodialysis System received U.S. Food and Drug Administration (FDA) clearance for use in professional care settings in August 2024.

“The dialysis space has been overdue for innovation, and Diality is delivering it,” Donato stated. “I look forward to joining the team at Diality and leveraging my experience in growing and scaling companies and financial infrastructure to bring much-needed innovation to the renal/kidney space.”

Diality is a medical device company developing solutions for kidney disease treatment. The Moda-flx Hemodialysis System is a user-friendly, mobile, and connected hemodialysis platform designed to maximize clinical flexibility by combining prescription capabilities of in-center systems with the ease-of-use of next-generation hemodialysis devices.